NICE spurns Imbruvica, but opens door to CDF

In draft guidance, the U.K.'s NICE recommended against use of Imbruvica ibrutinib from Johnson & Johnson (NYSE:JNJ) and AbbVie Inc. (NYSE:ABBV) to treat chronic lymphocytic leukemia (CLL) in patients

Read the full 292 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE